Literature DB >> 2067757

Age-specific differences in the relationship between oral contraceptive use and breast cancer.

P A Wingo1, N C Lee, H W Ory, V Beral, H B Peterson, P Rhodes.   

Abstract

Nearly all studies have suggested that the use of oral contraceptives (OC) is not associated with the aggregate risk of breast cancer diagnosed in women aged 20-54. Because of age-specific differences in the breast cancer-parity relationship and because of age-specific differences in other breast cancer risk factors, the Centers for Disease Control reexamined data from the Cancer and Steroid Hormone Study to assess whether OC use has different effects on the risk of breast cancer at different ages of diagnosis. This was a population-based case-control study conducted in eight geographic areas in the United States during 1980-1982. In these data, the relationship between the risk of breast cancer and OC use appeared to vary by age at diagnosis. Among women aged 20-34 years at diagnosis or interview, those who had ever used OC had a slightly increased risk of breast cancer (odds ratio 1.4, 95% confidence interval 1.0-2.1) when compared with women of the same ages who had never used OC. Among these women, there were no trends of increasing or decreasing risk with any measure of OC use. Among women aged 35-44 years, there was no association between OC use and breast cancer. Among women aged 45-54 years, those who used OC had a slightly decreased risk of breast cancer (odds ratio 0.9, 95% confidence interval 0.8-1.0). Among these women, the risk estimates decreased significantly with increasing time since first and last use. Although the slightly increased risk estimates for the youngest women are compatible with findings by other investigators, the decreased risk estimates for the oldest women have not been described in as many studies. Available data provide no reasons for changes in prescribing practices or in the use of OC as related to breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067757

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

Review 1.  Injectable contraception with depot medroxyprogesterone acetate. Current status.

Authors:  Andrew M Kaunitz; Allan Rosenfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

2.  Recent oral contraceptive use and risk of breast cancer (United States)

Authors:  P A Newcomb; M P Longnecker; B E Storer; R Mittendorf; J Baron; R W Clapp; A Trentham-Dietz; W C Willett
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

3.  Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Authors:  Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-14       Impact factor: 4.254

4.  Risk of breast cancer in relation to the interval since last full term pregnancy.

Authors:  P Cummings; J L Stanford; J R Daling; N S Weiss; B McKnight
Journal:  BMJ       Date:  1994-06-25

5.  Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year.

Authors:  L Tryggvadóttir; H Tulinius; G B Gudmundsdóttir
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Oral contraceptive use and breast cancer risk among African-American women.

Authors:  J R Palmer; L Rosenberg; R S Rao; B L Strom; M E Warshauer; S Harlap; A Zauber; S Shapiro
Journal:  Cancer Causes Control       Date:  1995-07       Impact factor: 2.506

Review 7.  Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk.

Authors:  I A Mustafa; K I Bland
Journal:  Ann Surg       Date:  1998-11       Impact factor: 12.969

8.  Oral contraceptive use and risk of breast cancer in older women (New Zealand).

Authors:  C Paul; D C Skegg; G F Spears
Journal:  Cancer Causes Control       Date:  1995-11       Impact factor: 2.506

9.  Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study.

Authors:  Marit Busund; Nora S Bugge; Tonje Braaten; Marit Waaseth; Charlotta Rylander; Eiliv Lund
Journal:  Int J Cancer       Date:  2018-02-07       Impact factor: 7.396

10.  Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.

Authors:  Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Patricia Moorman; Beth Newman; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.